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1. Introduction 
Adolescents have 2/3 of total population. This 
is a unique group with special needs and 
attention. Most adolescents with lifestyle issues 
fell in the age group of 16–18 years. Adolescence 
is an important transition in an individual's life. 
Turmoil which one experiences in this period-has 
greater effects onto the behavioral aspects of an 
individual. If one divides the whole stream of an 
individual's life into certain urbitrary segments, 
then adolescence is that period of life which lies 
between childhood and adulthood (1-4). Although 
there is no definite day or hour when childhood 
ends and adolescence begins, it has become 
conventional to fix upon the first signs of 
reproductive power as the beginning of 
adolescence. But the age of the onset of such 
reproductive power (popularly known as 
'puberty') varies with the climates, with race, with 
intelligence, and with some such other conditions 
(5-8). 
It is standard methods of adherence 
monitoring for prescribed substances, for 
example, self-reporting and monitoring of 
symptoms or patient behaviors, are unreliable for 
controlled substances. Though volumes have been 
made available by the previous researchers on 
several aspects of adolescents problem, still the 
'problems of adolescence as such is quite novel 
even in the present era and that is because of its 
crucial and delicate impact on to the individual as 
well as to the society (9-12). 
Studies so far reported on various problems of 
adolescence in the country and abroad cover a 
wide range starting from problems of adjustment 
in general (13-14), to the problems of adjustment 
in context to cross-cultural variations (15), in 
rural and urban adolescents (16), in context to 
personality and motivational aspects of 
adolescents (17-18).  
A scrutiny of these studies gives an 
impression ‗that there is as yet lack of agreement 
amongst these authors regarding the onset as well 
as duration of adolescence in an individual's life. 
This is so stated because in some' of these studies 
the subjects (Ss) selected were in the age range of 
14 to 18 years, in some others 15 to 17 and in 
some others the beginning of adolescence was 
thought to be as early as 12 years, and still in 
some others no mention of the age of the subjects 
was made but that they were all undergraduate 
students (19). In none of these studies any 
justification for selecting subjects within this age 
range was mentioned. Perhaps following Western 
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literature it has been assumed in these studies that 
the classical age range of adolescence is between 
14 to 18 years. If this assumption is true, then 
certainly it is subject to criticism since there are 
wide cross-cultural and sub-cultural 0 variations 
in the onset of adolescence (20). Thus, e.g., for 
the girls of Western cultures the beginning of 
adolescence has been reported to vary between 
age 9 to 20 years or even later depending upon 
whether she is Italian, English or Finns (21). 
An important consequence of our modern-day 
society is that it is difficult for children and 
caregivers both to get adequate sleep. Sleep 
involves reciprocal interactions between all 
members of a household as well as with the 
environment of the home and outside. 
Materials and Methods 
Drugs, chemicals and other substances 
consumed by humans are often excreted in the 
urine, where they may be detected with screening 
tests. The detection of these compounds is limited 
only by the assay and cost. 
Forensic versus clinical urinary drug testing  
Historically drug testing has been forensic in 
nature and has assumed most donors will provide 
a negative specimen. In patient-centered UDT in a 
clinical setting, the majority of specimens 
provided are expected to be positive for a broad 
range of drugs that are prescribed for medical 
purposes which adds to the complexity of the 
testing and the interpretation of data. Most UDT 
today that involves drug testing laboratories 
includes elements of both forensic drug testing 
and clinical drug testing. Drug testing in clinical 
settings also includes toxicology testing, usually 
in hospital emergency departments or emergency 
psychiatry settings, used to help accurately 
diagnose possible drug poisoning or overdose. 
Clinical drug testing is often inaccurately labeled 
as ―toxicology testing‖ involving ―tox screens‖ 
when the goal of testing is not to identify a case 
of acute poisoning but is to assist in treatment 
planning for a chronic disease, such as chronic 
non cancer pain or addiction. 
In forensic drug testing, results are meant to 
stand up to legal challenges and meet the rules of 
evidence in legal proceedings. Chain-of-custody 
procedures, secure storage of samples, and 
stringent method validations are utilized with the 
aim of minimizing or eliminating false positive 
results, and rigorous laboratory certification 
programs are used to assure quality. The 
personnel running the tests in a forensic UDT 
laboratory usually have training in chemistry or 
forensic science and they understand chain-of-
custody and medicolegal requirements In hospital 
or pathology laboratories the emphasis is typically 
on drugs of abuse, screening either for 
compliance to (e.g. methadone) or abstinence 
from (e.g. cannabis) particular substances. 
Hospital screening can also give the clinician 
additional help in the differential diagnosis and 
treatment of a patient, but the availability of 
toxicological analyses varies between hospitals. 
Most commonly used drug screening tests 
involve immunoassay techniques. These range 
from so-called bedside or point-of-care testing to 
more sophisticated laboratory based 
immunological tests. Immunoassay can provide 
fast and reliable results, however the results must 
be interpreted with caution. 
2. Results and Discussion 
Urine drug test in clinical practice, like any 
other medical test, should be performed to 
improve patient care. Inappropriate interpretation 
of results, as with any other diagnostic test, may 
adversely affect patient care: for example, 
discharge of patients from care when prescribed 
drugs are not detected and over- or under-
diagnosis of substance misuse or addiction. 
Health care professionals should use UDT results 
in conjunction with other clinical information. 
Consultation with an individual knowledgeable in 
UDT interpretation (eg.: laboratory director or 
toxicologist) is strongly encouraged, especially 
when unexpected test results are obtained. The 
testing laboratory or POC device manufacturer 
should provide readily accessible consultation and 
results interpretation. 
Interpretation of UDT results  
The valid detection period for drug exposure 
varies depending on the disposition characteristics 
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of the drug, dose, and frequency of use. Specific 
characteristics of a urine sample include its 
appearance, temperature within 4 minutes of 
voiding, pH, creatinine concentration, and 
specific gravity. The color of urine is based on the 
concentration of its constituents and can vary 
based on medications, foods, or disease states; 
excess hydration can cause it to appear colorless. 
Concentrated urine specimens are usually more 
reliable than dilute specimens. 
 
Table 1 Interpretation of urine drug test 
 Patient has taken drug Patient has not taken drug 
Positive test result True Positive False Positive 
Negative test result False negative True negative 
 
In this context, the sensitivity of a test is the 
ability to detect a class of drugs, while the 
specificity is the ability to identify a particular 
drug. A highly specific test gives few false-
positive results and identifies individual drugs 
and/or their metabolites. High sensitivity is due, 
in part, to the test‘s ability to detect both the 
parent drug and/or its metabolite(s), combined, to 
reach the cutoff concentration for a positive 
report. 
Sensitivity and specificity 
The qualitative immunoassay drug panel 
reports each sample as either positive or negative 
for a particular drug or drug class, based on 
predetermined cutoff concentrations. In the ideal 
world, UDT would be positive if the patient took 
the drug (true-positive) and negative if the drug 
was not taken (true-negative). However, false-
positive or false-negative results can occur, so it 
is imperative to interpret UDT results carefully. In 
addition, testing technology is constantly evolving 
and varies by manufacturer, so false-positive or 
false-negative results today may not be relevant in 
the future. 
Cross-Reactivity 
Detection of a particular drug by a drug-class–
specific immunoassay depends on the structural 
similarity of that drug or its metabolite(s) to the 
compound used for standardization, and the urine 
concentration of that drug/metabolite, compared 
with the standardizing compound.9 For example: 
Tests for cocaine react principally with cocaine 
and its primary metabolite, benzoylecgonine. 
These tests have low crossreactivity with other 
substances and, therefore, presence of cocaine 
(detected only with very recent use because of a 
short half-life) or benzoylecgonine is highly 
predictive of cocaine use. 
Tests for amphetamine/methamphetamine are 
highly crossreactive. They may detect other 
sympathomimetic amines such as ephedrine and 
pseudoephedrine and, therefore, are less reliable 
for amphetamine/methamphetamine use. Further 
testing may be required by a more specific 
method, such as GC/MS and stereospecific 
chromatography. 
Immunoassay testing for opiates is very 
responsive for morphine and codeine, but does 
not distinguish which is present. However, it 
shows a lower sensitivity for semisynthetic/ 
synthetic opioids, and so even large 
concentrations in the urine may not be reliably 
detected by the opiate immunoassay. A negative 
result does not exclude use of these opioids, but 
the ability of opiate immunoassays to detect 
semisynthetic/synthetic opioids varies among 
assays because of differing cross-reactivity 
patterns. Specific immunoassay tests for some 
semisynthetic/ synthetic opioids may be available 
(eg, oxycodone, methadone/EDDP). 
Therefore, for clinical purposes, the cocaine 
assay would be very reliable, while the 
amphetamine assay would be unreliable in 
predicting use of the drug, and the opiate assay 
would be unreliable in predicting use of 
semisynthetic/synthetic opioids. Fortunately, 
GC/MS or LC/MS analysis directed toward a 
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particular molecule on the same urine specimen 
will normally detect these semisynthetic and 
synthetic opioids. It is important to contact the 
laboratory when looking for a specific substance 
to ensure that the correct test/profile is used. 
Cross-reacting compounds can also be 
structurally unrelated to the standardizing 
compound. For example, several quinolone 
antibiotics (eg, levofloxacin, ofloxacin) can 
potentially cause false-positive results for opiates 
by some common immunoassays, despite no 
obvious structural similarity with morphine. 
Quinolones are not misidentified as opiates by 
GC/MS or LC/MS. There have also been cases of 
false-positive fentanyl results with some 
immunoassays for patients who are taking the 
antidepressant trazodone and the antidepressant 
venlafaxine can cause false-positive PCP results 
with some immunoassays. Examples of other 
agents that can cause false-positive immunoassay 
results are shown in Table 4.2. Interferences from 
some of the drugs listed have been eliminated by 
some manufacturers, and other interferences are 
expected to arise as tests are modified and new 
drugs come to market. 
Table 2 Examples of cross-reacting compounds for certain immunoassays 
Interfering drug Immunoassay Interfering drug affected 
Quinolone antibiotics(eg, levofloxacin, ofloxacin) Opiates 
Antidepressant trazodone Fentanyl 
Antidepressant venlafaxine Phencyclidine 
Atypical antipsychotic quetiapine Methadone 
Antiretroviral efavirenz THC 
Diet pills (eg, clobenzorex, fenproporex) Amphetamine 
Promethazine (for allergies, agitation, nausea, 
vomiting) 
Amphetamine 
l-methamphetamine (over-the-counter nasal inhaler) Amphetamine 
Dextromethorphan Phencyclidine 
Proton pump inhibitors (such as pantoprazole) THC 
 
Drug Metabolites 
In general, the concentration of the parent drug in 
urine exceeds that of its metabolite(s). In certain 
cases, UDT may detect traces of unexplained 
opioids (Figure 4.1) For example, a patient who is 
prescribed codeine may show trace quantities of 
hydrocodone that may not represent hydrocodone 
use. Detection of minor amounts of hydrocodone 
in urine containing a high concentration of codeine 
should not be interpreted as evidence of 
hydrocodone use. In the case of a patient who is 
prescribed hydrocodone, quantities of 
hydromorphone may be detected because of 
hydrocodone metabolism. However, the detection 
of trace amounts of a potential metabolite in the 
absence of its parent may be a timing of 
administration issue rather than coadministration 
of a second drug. As with any unexplained test 
result, it is important to clarify the interpretation 
with someone knowledgeable in clinical 
toxicology. 
Not comprehensive pathways, but may explain the 
presence of apparently unprescribed drugs 
6-MAM-6-monoacetylmorphine. 
Opioid Metabolism 
Codeine is metabolized to morphine, so both 
substances may occur in urine following codeine 
use. 
A prescription for codeine may explain the 
presence of both drugs in urine. 
A prescription for codeine does not normally 
explain the presence of only morphine.* This is 
most consistent with use of morphine or heroin. 
Prescribed morphine cannot account for the 
presence of codeine. 
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Codeine metabolizes to morphine, but the reverse 
does not occur. 
Codeine alone is possible because a small 
proportion of patients (7% of the Caucasian 
population) lack the necessary activity of the 
cytochrome P450 (CYP) 2D6 enzymatic pathway 
to convert codeine to morphine. 
Metabolism of codeine would not result in the 
presence of hydromorphone. 
Morphine may be metabolized to produce small 
amounts (generally <10%) of hydromorphone. 
Hydrocodone may be metabolized to small 
quantities of hydromorphone. 
Metabolism of codeine may produce small 
quantities of hydrocodone. 
Oxycodone is metabolized by CYP3A4 to 
noroxycodone and by CYP2D6 to oxymorphone. 
If the urine of a patient prescribed oxycodone tests 
positive for oxymorphone, a quantitative analysis 
should confirm—in the majority of cases—that the 
relative concentration of oxycodone is greater than 
oxymorphone. Test results for patients prescribed 
oxymorphone are easier to interpret because 
oxymorphone does not produce any metabolites 
that can be mistaken for another opioid (although 
oxymorphone tablets may contain up to 1% 
oxycodone as a manufacturing byproduct, which 
should generally not be detectable with UDT). 
Cocaine: Cocaine is a topical anesthetic clinically 
used in certain trauma, dental, ophthalmologic, and 
otolaryngologic procedures. A patient‘s urine may 
test positive for the cocaine metabolite, 
benzoylecgonine, after such a procedure for up to 
2 to 3 days. However, a licensed health care 
professional must order its use, which can be 
checked through medical records or by contacting 
the treating health care professional. There is no 
structural similarity between other topical 
anesthetics that end in ―caine‖ (eg, prilocaine, 
lidocaine) and cocaine or benzoylecgonine; 
therefore, cross-reaction does not occur.A positive 
UDT result for the cocaine metabolite, in the 
absence of a medical explanation, should be 
interpreted as due to deliberate use. 
Amphetamine/Methamphetamine:  
Clinical interpretation of positive amphetamine 
and methamphetamine results can be challenging 
because of the structural similarities to many 
prescription and OTC products, including diet 
agents, decongestants, and selegiline used in the 
treatment of Parkinsons disease. Knowledge of 
potential sources of amphetamine and 
methamphetamine can prevent misinterpretation of 
results. The traditional GC/MS criteria for 
reporting a positive methamphetamine result is not 
sufficient to distinguish methamphetamine use 
from use of OTC products. Methamphetamine 
exists as 2 isomers that are designated d- and l-.8 
The d-form has a strong stimulant effect on the 
central nervous system (CNS) and high misuse 
potential, while the l-form in therapeutic doses has 
a primarily peripheral action and is found in some 
OTC preparations. Routine testing, such as 
immunoassays or GC/MS, does not differentiate 
between the d- and l-forms. In a case of disputed 
amphetamine or methamphetamine misuse, 
stereospecific chromatography may be used in 
addition to GC/MS. For example, the OTC Vicks® 
Inhaler marketed in the United States contains l-
desoxyephedrine (l-methamphetamine).8 Patients 
whose management includes UDT should be 
advised not to use the Vicks® Inhaler or similar 
OTC preparations containing this agent because 
they can interfere with the interpretation of UDT 
results; this is particularly important in a 
community with a high incidence of 
methamphetamine misuse. Misuse of even the l-
form can have significant CNS activity and should 
be addressed clinically with the patient. 
Interpretation of results  
Clinicians‘ predictions of UDT results are often 
inaccurate and evidence suggests a majority of 
physicians have a poor understanding of how to 
interpret UDT results. Others may have a false 
sense of confidence about interpreting their 
patients‘ UDT results because they lack specific 
knowledge or don‘t fully understand the breadth of 
abnormal or unexpected toxicology findings that 
are possible 
3. Conclusion 
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Adolescents need to be treated as a distinct 
segment of our population and it is important to 
realize and address their health and lifestyle 
problems. Urine drug testing can be an effective 
tool for health care professionals in the assessment 
and ongoing management of patients who:  
Have or may have the disease of addiction 
Have other relevant medical conditions or 
diagnoses 
Will be, or are being, treated over the long term 
with controlled substances, including opioids (not 
for acute pain) 
The demands on young people are new and 
unprecedented; their parents could not have 
predicted many of the pressures they face. How we 
help adolescents meet these demands and equip 
them with the kind of education, skills, and 
outlook they will need in a changing environment 
will depend on how well we understand their 
world. Because substance-use disorders are 
common, UDT should be considered a core tool in 
primary care. The clinician can use a discordant 
UDT result to motivate patient behavior change. 
However, testing without an appropriate strategy 
for interpreting results can do harm. A working 
relationship with the testing laboratory or test kit 
provider is essential to accurately interpret UDT 
results. Most importantly, a health care 
professional should strive for a relationship of 
mutual honesty and trust with the patient when 
using UDT in his or her clinical practice. 
Therefore, the use of UDT should be consensual, 
be designed to help patients, and assist health care 
professionals to advocate for the health and well-
being of their patients. Further research studies 
should be carried out to highlight issues of concern 
and their possible solutions in this population 
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